Abstract
Current treatment of high-grade osteosarcoma combines surgical removal of the lesion with chemotherapy. In this study we evaluated whether the expression of P-glycoprotein, a protein closely associated with multidrug resistance, may be helpful in identifying the patients whose tumours will be further resistant to specific agents. By using multidrug-resistant osteosarcoma cell lines as standards, the expression of P-glycoprotein was evaluated in 105 cases of primary and metastatic osteosarcoma by semiquantitative immunofluorescence. Overexpression of the protein was shown in 23% of primary and in 50% of metastatic lesions. In 38 cases, homogeneously treated and followed-up for at least 24 months, overexpression of P-glycoprotein appeared to be associated with a higher relapse rate and with a trend toward a worse outcome. These data support the role of P-glycoprotein in the response to chemotherapy and its involvement in the determination of the outcome of osteosarcoma patients.
| Original language | English |
|---|---|
| Pages (from-to) | 1998-2002 |
| Number of pages | 5 |
| Journal | European Journal of Cancer |
| Volume | 31 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - 1995 |
Fingerprint
Keywords
- chemotherapy
- immunofluorescence
- multidrug resistance
- osteosarcoma
- P-glycoprotein
ASJC Scopus subject areas
- Cancer Research
- Oncology
- Hematology
Cite this
Analysis of P-glycoprotein expression in osteosarcoma. / Serra, M.; Scotlandi, K.; Manara, M. C.; Maurici, D.; Benini, S.; Sarti, M.; Campanacci, M.; Baldini, N.
In: European Journal of Cancer, Vol. 31, No. 12, 1995, p. 1998-2002.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Analysis of P-glycoprotein expression in osteosarcoma
AU - Serra, M.
AU - Scotlandi, K.
AU - Manara, M. C.
AU - Maurici, D.
AU - Benini, S.
AU - Sarti, M.
AU - Campanacci, M.
AU - Baldini, N.
PY - 1995
Y1 - 1995
N2 - Current treatment of high-grade osteosarcoma combines surgical removal of the lesion with chemotherapy. In this study we evaluated whether the expression of P-glycoprotein, a protein closely associated with multidrug resistance, may be helpful in identifying the patients whose tumours will be further resistant to specific agents. By using multidrug-resistant osteosarcoma cell lines as standards, the expression of P-glycoprotein was evaluated in 105 cases of primary and metastatic osteosarcoma by semiquantitative immunofluorescence. Overexpression of the protein was shown in 23% of primary and in 50% of metastatic lesions. In 38 cases, homogeneously treated and followed-up for at least 24 months, overexpression of P-glycoprotein appeared to be associated with a higher relapse rate and with a trend toward a worse outcome. These data support the role of P-glycoprotein in the response to chemotherapy and its involvement in the determination of the outcome of osteosarcoma patients.
AB - Current treatment of high-grade osteosarcoma combines surgical removal of the lesion with chemotherapy. In this study we evaluated whether the expression of P-glycoprotein, a protein closely associated with multidrug resistance, may be helpful in identifying the patients whose tumours will be further resistant to specific agents. By using multidrug-resistant osteosarcoma cell lines as standards, the expression of P-glycoprotein was evaluated in 105 cases of primary and metastatic osteosarcoma by semiquantitative immunofluorescence. Overexpression of the protein was shown in 23% of primary and in 50% of metastatic lesions. In 38 cases, homogeneously treated and followed-up for at least 24 months, overexpression of P-glycoprotein appeared to be associated with a higher relapse rate and with a trend toward a worse outcome. These data support the role of P-glycoprotein in the response to chemotherapy and its involvement in the determination of the outcome of osteosarcoma patients.
KW - chemotherapy
KW - immunofluorescence
KW - multidrug resistance
KW - osteosarcoma
KW - P-glycoprotein
UR - http://www.scopus.com/inward/record.url?scp=0029564659&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029564659&partnerID=8YFLogxK
U2 - 10.1016/0959-8049(95)00335-5
DO - 10.1016/0959-8049(95)00335-5
M3 - Article
C2 - 8562155
AN - SCOPUS:0029564659
VL - 31
SP - 1998
EP - 2002
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
IS - 12
ER -